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The rat cytomegalovirus (RCMV) R33 gene is conserved among all betaherpesviruses and encodes a protein
(pR33) that shows sequence similarity with chemokine-binding G protein-coupled receptors (GPCRs). Previ-
ously, the physiological significance of the R33 gene was demonstrated by the finding that an RCMV strain with
R33 deleted is severely attenuated in vivo and is unable to either enter or replicate in the salivary glands of
infected rats. Here, we report that RCMV pR33 is expressed as a functional GPCR that signals in an
agonist-independent manner in both COS-7 and Rat2 cells. Transient expression of pR33 in COS-7 cells
results in constitutive activation of phospholipase C (PLC) due to coupling to G proteins of the Gq class.
Interestingly, PLC activation is partially inhibited by cotransfection with G-transducin subunits, which
indicates the involvement of G as well as G subunits in pR33-mediated signaling. Surprisingly, PLC
activation is also partially inhibited by addition of pertussis toxin (PTX), suggesting that pR33 activates not
only Gq but also Gi/0 proteins. The constitutive activation of Gi/0 proteins by pR33 is further demonstrated by
the PTX-sensitive decrease of CRE-mediated transcription and the PTX-sensitive increase of both NF-B- and
SRE-mediated transcription. In contrast to its homolog of human herpesvirus 6B (pU12), pR33 does not bind
RANTES.
Cytomegaloviruses (CMVs) are species-specific betaherpes-
viruses that cause acute, persisting, and latent infections in
both humans and animals. The ability of CMVs to induce
lifelong, latent infections implies that these viruses are highly
adapted to their hosts. Specifically, they will have to employ
sophisticated strategies in order to remain hidden from their
host’s immune system. Among the CMV genes that are likely
to be involved in these strategies are those encoding homologs
of crucial immune effector or regulatory proteins of the host,
such as G protein-coupled receptors (GPCRs). These genes
have probably been pirated by the virus during the long coevo-
lution of pathogen and host.
GPCRs form a large and diverse family of receptors that
function in signal transduction through cell membranes. They
are composed of a central core domain consisting of seven
transmembrane helices connected by three intracellular and
three extracellular loops. The majority of these receptors ac-
tivate G proteins and are capable of transducing a wide variety
of messages. Within the genomes of all sequenced CMVs,
genes have been identified that potentially encode homologs of
host cellular GPCRs. Human CMV (HCMV) carries four of
these genes: US27, US28, UL33, and UL78 (13, 14). Only two
of these, UL33 and UL78, were found to have counterparts in
rat CMV (RCMV) (R33 and R78, respectively [4, 5, 52]) as
well as murine CMV (MCMV) (M33 and M78, respectively
[17, 41]). Of the predicted amino acid sequences derived from
the CMV GPCR-like genes, those encoded by HCMV US27
and US28 were found to have the highest similarity to chemo-
kine-binding GPCRs (chemokine receptors). HCMV US28
was demonstrated to encode a functional chemokine receptor
(pUS28) which binds the CC (or -) chemokines RANTES,
MCP-1, MCP-3, MIP-1, and MIP-1 (7, 8, 22, 31, 37) as well
as the only known member of the CX3C (or -) chemokine
family, CX3CL1 (also known as fractalkine or neurotactin),
which is a membrane-associated chemokine with a cytoplasmic
domain (29). Upon CC-chemokine binding, pUS28 was shown
to engage in intracellular signaling by the mobilization of in-
tracellular calcium and activation of extracellular signal-re-
lated kinase 2 (7). Remarkably, pUS28 was also found to signal
in the absence of exogenously added chemokines, by activating
phospholipase C (PLC) as well as NF-B in transiently trans-
fected COS-7 cells (11). This constitutive, agonist-independent
activity of pUS28 can be modulated by fractalkine, which acts
as a partial inverse agonist, whereas CC-chemokines appear to
function as neutral antagonists (11). Another intriguing prop-
erty of pUS28 was identified by Streblow and colleagues (49).
They demonstrated that HCMV infection of primary arterial
smooth muscle cells (SMCs) resulted in cellular migration,
whereas an HCMV recombinant that lacks a functional US28
gene was unable to promote migration. The expression of
pUS28 in SMCs in the presence of CC-chemokines was suffi-
cient to induce migration. It was hypothesized by Streblow et
al. that HCMV may be using SMCs as a cellular vehicle to
disseminate the virus in vivo (49).
As described above, the HCMV UL33 gene has homologs in
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all sequenced betaherpesviruses, which underlines the biolog-
ical relevance of the UL33 gene family. At present, this family
consists of six members: HCMV UL33 (13, 14), MCMV M33
(41), and RCMV R33 (5) and the U12 genes of human her-
pesvirus 6A (HHV-6A) (24), HHV-6B (19, 25), and HHV-7
(38). The predicted amino acid sequences of the proteins en-
coded by the UL33-like gene family were found to comprise
several features characteristic of chemokine receptors (5, 17).
In addition, we found limited but significant sequence similar-
ity between the UL33 family members and mammalian che-
mokine receptors CCR3 and, in particular, CCR10 (54).
The biological significance of the UL33 family members has
previously been demonstrated in studies using recombinant
CMVs that carry either a disrupted UL33 (33), M33 (17), or
R33 gene (5) in their genomes. In cell culture, each of these
mutant viruses replicated with similar efficiency as the corre-
sponding wild-type (WT) viruses (5, 17, 33). However, during
in vivo infection, significant differences were observed between
animals infected with the recombinants and those infected with
the WT viruses. In contrast to their WT counterparts, viruses
with M33 and R33 deleted could not be detected within the
salivary glands of infected mice and rats, respectively (5, 17).
This indicated that M33 and R33 play a role in virus dissemi-
nation to or replication in the salivary glands (5, 17). Further-
more, it was shown in the RCMV-rat model that R33 also has
a more general function: a significantly lower mortality was
seen among rats infected with RCMV from which R33 was
deleted (RCMVR33) than among those infected with WT
RCMV (5). These results stressed the importance of the
UL33-like genes in the pathogenesis of CMV infection.
Although the HHV-6B member of the UL33 family, pU12,
was reported to be a calcium-mobilizing receptor for several
CC-chemokines (25), not much is known about the biochem-
ical, immunological, and pharmacological processes in which
the CMV members of this protein family may function. We
therefore set out to study the putative signaling properties of
the RCMV R33-encoded protein (pR33). We report here that
pR33 is a functional GPCR that signals in an agonist-indepen-
dent, constitutive fashion in COS-7 as well as Rat2 cells.
MATERIALS AND METHODS
Expression constructs. The sequence containing RCMV open reading frames
(ORFs) R32 (partially), R33, and R34 (partially) (position 24384 to 29545 of the
RCMV genome sequence [53]) was cloned as a PstI fragment into vector
pUC119, generating plasmid RPst5. This plasmid was digested with PvuI, and the
resulting 2.9-kb fragment, which contains the complete R33 ORF, was treated
with T4 DNA polymerase in the presence of deoxynucleoside triphosphates
(dNTPs) in order to generate blunt ends. Subsequently, the blunt-ended frag-
ment was cloned into the HincII restriction site of pUC119, generating plasmid
p375. Then, a PCR-based procedure was used to change the sequence around
the translation initiation codon of R33, 5-CGGTATGGAC-3, into the se-
quence 5-CGCCATGGAC-3, which contains an NcoI restriction site (indicated
in italics). This was carried out as follows. First, the 5 end of R33 was amplified
by means of PCR using primers R33.N-F and R33.N-R (Table 1) and p375 as a
template. Then, the 228-bp PCR product was treated with T4 DNA polymerase
and cloned into the HincII site of pUC119, creating plasmid pre-379. The se-
quence upstream of R33 was amplified by PCR using primers R32.N-F and
R32.N-R (Table 1) and p375 as a template. The 745-bp PCR product was treated
with T4 DNA polymerase and subsequently digested with NcoI. The resulting
NcoI-blunt fragment was cloned into pre-379 by using the SmaI site of the
polylinker and the introduced NcoI site at the translation initiation codon of R33,
resulting in plasmid p379. Finally, the 946-bp BglII-BsrGI fragment from p375
was exchanged for the BglII-BsrGI fragment from p379, which contains the
introduced NcoI site at the start codon of R33, generating plasmid p383. The
2.1-kb BamHI-SmaI fragment from p383, containing ORF R33 with the intro-
duced NcoI site, was cloned into BamHI- and HincII-digested pUC119. Subse-
quently, the 331-bp BamHI-NcoI fragment immediately upstream of R33 was
deleted from the plasmid by digestion with BamHI and NcoI and treatment with
the Klenow fragment of DNA polymerase I (Klenow) with dNTPs, followed by
closing of the linear vector with T4 DNA ligase, resulting in plasmid pUC119/
R33dN. The R33 expression vector pcDNA3/R33 was then generated by cloning
the 1,680-bp KpnI fragment containing ORF R33 from pUC119/R33dN into
KpnI-digested pcDNA3 (Invitrogen, Groningen, The Netherlands). The KpnI
sites of pUC119/R33dN are derived from the pUC119 polylinker, located 5 of
the translation initiation codon of ORF R33, and the RCMV sequence down-
stream of the ORF R33 stop codon (corresponding to position 27950 of the
RCMV sequence). The orientation of ORF R33 in pcDNA3/R33 was checked by
restriction enzyme analysis.
The expression vector pcDNA3/EGFP was generated by digestion of
pEGFP-N1 (Clontech, Palo Alto, Calif.) with BamHI and NotI and cloning the
resulting 739-bp fragment into BamHI- and NotI-digested pcDNA3. For the
construction of expression vector pcDNA3/EGFP-R33, a BspHI site was intro-
duced immediately downstream of the enhanced green fluorescent protein
(EGFP) ORF. This was carried out by means of PCR with primers GFP.CN-F
and EGFP.N1-R (Table 1), using pEGFP-N1 as a template. The amplified
fragment of 829 bp was treated with T4 DNA polymerase and the blunt-ended
fragment was subsequently cloned into HincII-digested pUC119, generating
pUC119-EGFP. Then, the 720-bp NcoI-BspHI fragment from pUC119/EGFP
was cloned into the introduced NcoI site at the translation initiation codon of
R33 within plasmid p383, resulting in plasmid p383-EGFP. The orientation of
the EGFP ORF was checked by restriction enzyme analysis. Then, p383-EGFP
was digested with NcoI and treated with Klenow. Subsequently, the DNA was
digested with ApaI to generate a 2.4-kb blunt-ApaI fragment which contains the
EGFP ORF fused to R33. This fragment was cloned into EcoRV- and ApaI-
digested pcDNA3, resulting in the expression vector pcDNA3/EGFP-R33.
TABLE 1. PCR primers used in this study
Primer Sequencea Restriction site(s) Source Positions Orientationb
GFP.CN-F 5-ATAAGAATTCCAGATCCGCTAGCGCTACCG-3 EcoRI pEGFP-N1 574–603 
EGFP.N1-R 5-TATATCGCGACTCATGAACTTGTACAGCTCGTCC-3 NruI, BspHI pEGFP-N1 1380–1403 
R32.N-F 5-TCGCAGATCTCCCGCCAGCCC-3 RCMV genome 25535–25555 
R32.N-R 5-TATACCATGGCGGTCCCGTCTCCGTC-3 NcoI RCMV genome 26253–26280 
R33.N-F 5-TAATCCATGGACGTGCTGCTGGGGAC-3 NcoI RCMV genome 26271–26290 
R33.N-R 5-GGTTCGTCATGTACAGGGTCGGCGTC-3 RCMV genome 26474–26499 
R33.C-F 5-TCCTGGTGGTGCAGACGCCGTTC-3 RCMV genome 27025–27047 
R33.C-R 5-CGTCTAGACAGTTCGGCGGCGGAC-3 XbaI RCMV genome 27415–27438 
R34.C-F 5-ACTGTCTAGACGGCAGATCGCCGCC-3 XbaI RCMV genome 27427–27451 
R34.C-R 5-GCTTCTCCGTCTCCCCGCGCC-3 RCMV genome 28024–28044 
a Underlined sequences indicate restriction enzyme recognition sites; sequences in boldface type differ from that of the original sequence as described in the columns
for source and positions.
b , orientation of the sequence is identical to the published sequence between the indicated positions; , sequence is complementary to the published sequence
between the indicated positions.
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In order to generate the pcDNA3/R33-EGFP expression vector, a pUC119
vector was created in which the SphI and XbaI sites of the polylinker were
destroyed (pre-376). This was carried out as follows. pUC119 was digested with
SphI and treated with T4 polymerase in the presence of dNTPs, and the linear
vector was closed with T4 DNA ligase. Subsequently, the vector was digested
with XbaI, treated with Klenow, and closed with T4 DNA ligase, generating
plasmid pre-376. The previously described 2.9-kb PvuI fragment containing the
complete R33 ORF was cloned into the HincII site of pre-376, generating
plasmid p376. Then, a PCR-based procedure was used to modify the sequence
around the stop codon of R33, 5-TGCTGAGTCG-3, into the sequence 5-TG
TCTAGACG-3, which contains an XbaI restriction site (in italics) and changes
the R33 stop codon to a leucine codon. This was performed as follows. First, the
3 end of ORF R33 was amplified by PCR with primers R33.C-F and R33.C-R
(Table 1), using p375 as a template. The 413-bp PCR product was digested with
SphI and XbaI and cloned into SphI- and XbaI-digested pUC119, generating
plasmid pre-380 (the SphI restriction site in R33 corresponds to position 27134
of the RCMV sequence). Then, the sequence downstream of the ORF R33 stop
codon was amplified by PCR with primers R34.C-F and R34.C-R (Table 1), using
p375 as a template. The amplified fragment of 617 bp was digested with Asp718
and XbaI and cloned into the corresponding sites of pre-380, resulting in plasmid
p380 (the Asp718 site in R34 corresponds to position 27947 of the RCMV
sequence). Finally, the 737-bp SphI-NruI fragment of p376 (the NruI restriction
site corresponds to position 27872 of the RCMV sequence) was exchanged for
the SphI-NruI fragment of p380, which contains the introduced XbaI site in the
R33 ORF, resulting in plasmid p384. Before the EGFP ORF could be cloned
immediately downstream of R33, a part of the sequence upstream of the EGFP
ORF in pEGFP-N1 was deleted. This was carried out by digestion of plasmid
pEGFP-N1 with BamHI and BglII and subsequent closing of the linearized
vector, resulting in plasmid p368. Then, the 768-bp NheI-XbaI fragment from
plasmid p368, which contains the EGFP ORF, was cloned into the introduced
XbaI site of R33 in p384, resulting in plasmid p384-EGFP. The orientation of the
EGFP ORF was checked by restriction enzyme analysis. Plasmid p384-EGFP
was digested with BamHI and NotI, and the resulting 2.3-kb fragment containing
the R33 ORF fused to EGFP was cloned into BamHI- and NotI-digested
pcDNA3, resulting in the expression vector pcDNA3/R33-EGFP.
The cDNA encoding HCMV US28 (AD169 strain) in pcDNA3 (pcDNA3/
US28) (11) was obtained from R. Doms (University of Pennsylvania, Philadel-
phia). The cDNA encoding human CCR10 (26) in pcDNA3 (pcDNA3/CCR10)
was obtained from C. Gerard (Ina Sue Perlmutter Laboratory, Boston, Mass.).
The cDNA of human CCR3 in pcDNA1 was provided by C. Tensen (Free
University, Amsterdam, The Netherlands). The CCR3 cDNA was recloned in
pcDNA3 by cutting the CCR3 fragment out of pcDNA1 using the flanking XbaI
and HindIII sites in the pcDNA1 polylinker and cloning the fragment in the
corresponding polylinker sites of pcDNA3, creating pcDNA3/CCR3. The
pcDNA3-derived vectors expressing G protein receptor kinase 2 (GRK2)
(pcDNA3/GRK2) and GRK2K220R (pcDNA3/GRK2K220R) (18) were provided
by S. Cotecchia (University of Lausanne, Lausanne, Switzerland). The Gt, Gq,
G11, and G16 expression vectors (pcDNA3/Gt, pcDNA3/Gq, pCMV5/G11,
and pC1H1/G16, respectively) were kind gifts from B. Defize (Hubrecht Lab-
oratory, Utrecht, The Netherlands), B. Conklin (University of California, San
Francisco), H. Umemori (University of Tokyo, Tokyo, Japan), and S. Rees
(University of Glasgow, Glasgow, United Kingdom), respectively. The reporter
plasmids pTLNC-21CRE and pTLNC-3SRE (21) were obtained from W. Born
(National Jewish Medical and Research Center, Denver, Colo.). The pNF-B-
Luc vector was purchased from Stratagene (La Jolla, Calif.). The integrity of all
DNA constructs was verified by sequence analysis.
Cell culture and transfection. COS-7 cells (ATCC CRL-1651) and Rat2 cells
(TK; ATCC CRL-1764) were cultured as described previously (4, 11). Trans-
fection of Rat2 cells was performed on 80% confluently grown monolayers by
using DEAE-dextran (final concentration, 0.4 mg/ml) in serum-free Eagle’s
minimal essential medium with Earle’s balanced salt solution (EMEM) supple-
mented with 2 mM L-glutamine, and 1	 nonessential amino acids (NEAA).
After 2 h of incubation at 5% CO2 and 37°C, the transfection medium was
aspirated and the cells were treated with 10% dimethyl sulfoxide in phosphate-
buffered saline (PBS) for 1 min. Subsequently, the cells were washed three times
with PBS and further grown at 5% CO2 and 37°C in serum-free EMEM con-
taining 2 mM L-glutamine and 1	 NEAA. Transfection of COS-7 cells was
carried out as described previously (11).
Confocal imaging. Transiently transfected cells (COS-7 or Rat2) were grown
on glass coverslips and were fixed for 20 min with 3.7% Formol in PBS 48 h after
transfection. To stain the trans-Golgi complex, cells were washed three times
with PBS and incubated with 1 
M Bodipy TR ceramide (Molecular Probes,
Leiden, The Netherlands) and 1% bovine serum albumin (BSA) (Sigma) in PBS
for 30 min at 4°C. For staining of the endoplasmic reticulum (ER), cells were
permeabilized with 0.05% NP-40 (Boehringer Mannheim, Mannheim, Germany)
in PBS for 20 min and subsequently incubated at 37°C for 1.5 h with mouse
monoclonal antibody IID8 (directed against SERCA 2) (ABR, Golden, Colo.) in
PBS containing 1% BSA, washed three times with PBS, and incubated for 1.5 h
at 37°C with rabbit anti-mouse–rhodamine (1:50 in PBS; DAKO, Glostrup,
Denmark). Thereafter, cells were washed three times with PBS and the cover-
slips were mounted in 90% glycerol containing 0.02 M Tris-HCl (pH 8.0),
0.002% NaN3, and 2% DABCO [1,4-diazabicyclo-(2,2,2)-octane; Merck, Darm-
stadt, Germany]. Confocal images were collected at wavelengths of 488 and 568
nm using an MRC 600 confocal microscope equipped with an oil immersion
objective (40	magnification, numerical aperture 1.3; Bio-Rad, Hemel Hemp-
stead, United Kingdom) as described previously (9). The digital images were
projected and merged using Confocal Assistance software from Bio-Rad
(Veenendaal, The Netherlands).
EGFP-based monolayer enzyme-linked immunosorbent assay (ELISA).
Transfected cells were seeded in 48-well plates (Costar). After 48 h of incuba-
tion, the monolayers were washed once with Tris-buffered saline (TBS) (50 mM
Tris, 150 mM NaCl [pH 7.5]) and fixed for 30 min with 4% paraformaldehyde in
PBS. Subsequently, cells were washed three times with TBS and permeabilized
with 0.5% NP-40 in TBS. After 30 min, the permeabilization solution was re-
placed with blocking buffer (1% fat-free milk, 0.1 M NaHCO3 [pH 8.6]) and the
cells were incubated for 4 h at room temperature. Then, the blocking buffer was
replaced with the primary antibody solution containing a 1:100 dilution of anti-
EGFP polyclonal antibody (Clontech) in TBS with 0.1% BSA. The cells were
incubated overnight at 4°C with shaking. The monolayers were washed three
times with TBS, after which the secondary antibody containing a 1:2,500 dilution
of goat anti-rabbit–horseradish peroxidase conjugate (Bio-Rad) was added. Af-
ter 2 h of incubation at room temperature, the cells were washed three times with
TBS and the OPD substrate solution (5 mM O-phenylenediamine [Sigma],
0.03% H2O2 in 0.1 M citrate–phosphate buffer [pH 5.0]) was applied for approx-
imately 10 min. The coloring reaction was stopped by the addition of 1 M H2SO4,
samples were taken from the supernatants, and the optical density was measured
in a Victor2 Wallac multilabel counter at 490 nm.
[3H]inositol phosphate production. Inositol phosphate production in trans-
fected COS-7 cells was determined as described previously (11).
Reporter assays. COS-7 cells were transiently transfected with one of the
following reporter plasmids: pNF-B-Luc (NF-B assay), pTLNC-21CRE (cyclic
AMP [cAMP]-responsive element [CRE] assay), pTLNC-3SRE serum-respon-
sive promoter element [SRE] assay) (5 
g/106 cells), and one of the GPCR-
expressing plasmids. Transfected cells were seeded in 96-well white plates
(Costar) in serum-free medium either in the presence or absence of pertussis
toxin (PTX) (100 ng/ml) (all assays) or human or rat RANTES (100 nM, NF-B
and SRE assay). To cells cotransfected with the CRE reporter plasmid, 10 
M
forskolin was added 24 h after transfection, either in the presence or absence of
human or rat RANTES (100 nM). After a 6-h incubation, luciferase activity was
assayed by aspiration of the culture medium and addition of 25 
l of luciferase
assay reagent (0.83 mM ATP, 0.83 mM D-luciferin [Duchefa Biochemie B.V.,
Haarlem, The Netherlands], 18.7 mM MgCl2, 0.78 
M Na2H2P2O7, 38.9 mM
Tris [pH 7.8], 0.39% [vol/vol] glycerol, 0.03% [vol/vol] Triton X-100, and 2.6 
M
dithiothreitol). After a 5-min incubation, the relative luminescence was mea-
sured for 3 s using a Victor2 Wallac multilabel counter. For cells transfected with
either the NF-B or the SRE reporter constructs, luciferase activity was mea-
sured 48 h after transfection using the same protocol.
Chemokine binding assay. Human and rat RANTES were labeled with 125I
using the Iodo-gen method (Pierce, Rockford, Ill.) according to the manufac-
turer’s protocol. 125I-labeled RANTES was separated from free iodine (99%)
using a 25-cm, 10-ml Sephadex G-25 gel filtration column (ICN Pharmaceuticals
Inc., Costa Mesa, Calif.). Iodine incorporation and specific activity were deter-
mined via precipitation of the protein by the trichloroacetic acid (TCA) method
(6). Transiently transfected cells were seeded in 24-well plates. In saturation
experiments, binding was performed 48 h after transfection on whole cells for 3 h
at 4°C using different concentrations of 125I-labeled human or rat RANTES
(from 0.1 to 6 nM) in binding buffer (50 mM HEPES [pH 7.4], 1 mM CaCl2, 5
mM MgCl2, and 0.5% BSA). Nonspecific binding was determined in the pres-
ence of 0.1 
M unlabeled competitor (human or rat RANTES). In competition
experiments, cells were incubated with 0.6 nM 125I-labeled human RANTES and
various amounts of unlabeled human or rat RANTES. After incubation, cells
were washed four times with binding buffer supplemented with 0.5 M NaCl.
Statistical analysis. All data shown are expressed as mean  standard error.
Statistical analysis was carried out by Student’s t tests. P values of 0.05 were
considered to indicate a significant difference.
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RESULTS
RCMV pR33 and pR33-EGFP signal constitutively in
COS-7 cells. To test whether the RCMV R33-encoded protein
(pR33) functions as a GPCR in vitro, we set out to examine the
effect of pR33 expression on the accumulation of inositol phos-
phates (InsP) in COS-7 cells. To this end, the cells were tran-
siently transfected with either of four different expression con-
structs, which encode native RCMV pR33 (pcDNA3/R33),
pR33-EGFP (pcDNA3/R33-EGFP), pEGFP-R33 (pcDNA3/
EGFP-R33) or no protein (pcDNA3). At 24 h after transfec-
tion, the cells were incubated with 3H-labeled inositol, and at
48 h after transfection, the accumulation of radiolabeled InsP
was measured. As shown in Fig. 1A, transfection of increasing
amounts of both pcDNA3/R33 and pcDNA3/R33-EGFP re-
sulted in increased [3H]InsP production within the cells. The
InsP production in cells transfected with pcDNA3/R33 and
pcDNA3/R33-EGFP only (4.0 
g/106 cells) was 3.2 times
higher than that in cells transfected with an equal amount of
pcDNA3 only. Interestingly, a significant difference in InsP
levels was not observed between pcDNA3- and pcDNA3/
EGFP-R33-transfected cells (data not shown). Taken together,
these data indicate that (i) these proteins activate signaling
pathways leading to increased InsP production rates and (ii)
these proteins signal in an agonist-independent fashion.
To examine the expression levels as well as intracellular
localization of the R33-encoded proteins, both ELISA and
confocal microscopy were performed. Since appropriate anti-
pR33 antibodies were unavailable, we could investigate only
the expression of the EGFP fusion proteins by virtue of the
presence of the EGFP tag in these proteins. The semiquanti-
tative, ELISA-based monolayer assay showed that transfection
of increasing amounts of pcDNA3/R33-EGFP resulted in in-
creasing intracellular levels of pR33-EGFP (Fig. 1B). By con-
trast, expression of pEGFP-R33 was not detected (data not
shown). These expression data are in agreement with the ac-
tivity of these EGFP-tagged proteins in the InsP accumulation
assay.
The cellular expression of pR33-EGFP was studied further
by confocal microscopy. Figure 1D shows that the EGFP flu-
orescence colocalizes with intracellular, perinuclear vesicles as
well as with the cell membrane of COS-7 cells transfected with
pcDNA3/R33-EGFP. This expression pattern differs consider-
ably from that seen in nonfused EGFP-expressing COS-7 cells,
in which EGFP is seen dispersed throughout the nucleus and
cytoplasm (Fig. 1C). These results strongly suggest that pR33-
EGFP is properly expressed on the cell surface of transfected
cells. In order to identify the intracellular vesicles to which
pR33-EGFP localized, we stained the cells either with a trans-
Golgi-specific marker (Bodipy TR ceramide) or with antibod-
ies directed against ER-specific SERCA proteins. However, as
shown in Fig. 1E and F, the EGFP signal does not colocalize
with the signals that were generated with these compartment-
specific markers. This indicated that pR33-EGFP localizes to
intracellular compartments other than ER or trans-Golgi. Nev-
ertheless, other attempts to identify these compartments have
not yet been undertaken. Whether the presence of pR33-
EGFP in these compartments is the consequence of high level
of expression of this protein is not known.
To evaluate the specificity of the constitutive activity of
pR33 in the InsP accumulation assay, we compared the activity
of this protein with that of two mammalian -chemokine re-
ceptors, CCR3 and CCR10, with which pR33 shares some
homology, and a constitutively active viral GPCR, HCMV
pUS28. As shown in Fig. 1G, cells transfected with either
pcDNA3/R33 or pcDNA3/US28 produced significantly higher
levels of InsP than cells transfected with either pcDNA3
(mock) or the mammalian GPCR expression constructs. These
data show that constitutive activity of GPCRs in the InsP assay
is not a general phenomenon but rather a characteristic of a
subset of receptors, as was recognized previously (11).
In summary, we have found pR33-EGFP to colocalize with
the cell membrane of transfected COS-7 cells and to induce
signaling pathways in an expression level-dependent fashion,
leading to the production of InsP. Since both pcDNA3/R33-
EGFP- and pcDNA3/R33-transfected cells demonstrate simi-
lar activities in the InsP assay, we infer that pR33 is expressed
on the surface of transfected cells in a similar fashion as was
demonstrated for pR33-EGFP.
pR33 couples to G proteins of the Gq and Gi/0 classes. An
intracellular rise in InsP levels is predominantly achieved fol-
lowing activation of PLC by G protein  subunits of the q class
(Gq). In addition, PLC activity can be stimulated by free G
protein  subunits (16). To investigate whether the constitu-
tive rise in InsP accumulation that is seen in cells expressing
pR33 and pR33/EGFP is indeed mediated through the inter-
action of these proteins with heterotrimeric G proteins, COS-7
cells were transfected with both pcDNA3/R33 and constructs
expressing either the G transducin subunit (Gt), GRK2, or
GRK2K220R. Gt is known to sequester  subunits, whereas
both GRK2 and GRK2K220R not only scavenge  subunits
but also specifically inhibit Gq activation (10, 20, 40). In
addition, in contrast to GRK2K220R, GRK2 can phosphorylate
GPCRs, leading to internalization and degradation of the re-
ceptors (18). As shown in Fig. 2A, cotransfection of pcDNA3/
R33 and pcDNA3/Gt resulted in a lower level of InsP
accumulation (80%) than transfection of pcDNA3/R33
(basal) alone (100%). However, even lower levels of InsP
were seen after cotransfection of pcDNA3/R33 and either
pcDNA3/GRK2 or pcDNA3/GRK2K220R (25 and 40%, re-
spectively). These InsP levels are similar to those measured
in pcDNA3-transfected cells (30%). Together, these results
suggest that the InsP production is mediated via coupling of
pR33 to  as well as Gq subunits. Since COS-7 cells
endogenously express only two members of the Gq class, Gq
and G11 (56), it is likely that the pR33-induced PLC activa-
tion is mediated by the  subunits of Gq and/or G11. In order
to confirm this interaction of pR33 with the  subunits of
Gq/11 and to investigate the putative interaction with an-
other member of the Gq family, G16, which is not ex-
pressed endogenously by COS-7 cells, cells were cotrans-
fected with both pcDNA3/R33 and constructs expressing
either Gq, G11, or G16. As shown in Fig. 2B, cotrans-
fection of pcDNA3/R33 with pCMV5/G11 resulted in a
higher level of InsP production (145%) than transfection of
pcDNA3/R33 alone (100%), whereas cotransfection of
pcDNA3/R33 with either pcDNA3/Gq or pC1H1/G16 did
not change InsP production levels significantly compared to
pcDNA3/R33 alone. These findings suggest that pR33 spe-
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cifically activates G11 in a constitutive fashion but does not
couple constitutively to Gq or G16.
Previously, it has been reported that PLC-activating  sub-
units can be released by G proteins of the Gi/0 class (16). To
examine if these Gi/0 proteins are also involved in pR33-mediated
constitutive PLC activation, we incubated pcDNA3- and
pcDNA3/R33-transfected cells in the presence of a Gi/0 inhibitor
(PTX), and measured the InsP accumulation. Figure 2A shows
that the InsP accumulation level in pcDNA3/R33-transfected
cells is significantly lower in the presence of PTX (75%) than in
the absence of PTX (100%), indicating that at least part of the
pR33-induced InsP production is mediated via Gi/0 proteins.
pR33-induced inhibition of CRE-mediated transcription.
The interaction of pR33 with G proteins of the Gi/0 class was
studied in more detail using the CRE reporter assay. This assay
allows detection of the inhibitory effect of activated Gi/0 sub-
units on adenylate cyclase (AC). The CRE assay is based on
FIG. 1. pR33- and pR33-EGFP-mediated induction of inositol
phosphate (InsP) accumulation. (A) COS-7 cells (106) were transiently
transfected with either pcDNA3, pcDNA3/R33, or pcDNA3/R33-
EGFP. At 48 h after transfection, the InsP accumulation was mea-
sured. (B) Expression of pR33-EGFP. COS-7 cells were transiently
transfected with various concentrations of pcDNA3/R33-EGFP. After
permeabilization, the cells were immunologically stained using an anti-
EGFP polyclonal antiserum. The staining was quantified by measuring
the optical density at 490 nm (OD490) by spectrophotometry. (C and
D) Cellular localization of EGFP (C) and pR33-EGFP (D). COS-7
cells were transiently transfected with either pcDNA3/EGFP or pcDNA3/
R33-EGFP, fixed, stained using propidium iodide (to visualize nucleic
acids), and subjected to confocal microscopy at 488 and 568 nm. (E)
Cellular localization of pR33-EGFP and the ER. pcDNA3/R33-EGFP-
transfected cells were stained using SERCA 2-specific antibodies. (F)
Cellular localization of pR33-EGFP and the Golgi apparatus. pcDNA3/
R33-EGFP-transfected cells were stained using a trans-Golgi marker.
Bars  5 
m. (G) Modulation of InsP accumulation by various recep-
tors. The InsP accumulation was determined after transient transfection
of COS-7 cells with either pcDNA3, pcDNA3/R33 (R33), pcDNA3/
CCR33 (CCR3), pcDNA3/CCR10 (CCR10), or pcDNA3/US28 (US28)
at 0.5 
g of DNA/106 cells. A representative experiment performed in
triplicate is shown. Each experiment was repeated at least twice. The
asterisks indicate a statistically significant difference (P  0.05) with
data from pcDNA3-transfected cells. Error bars, standard error of the
mean.
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the artificial stimulation of AC with forskolin, which results in
an increase of intracellular cAMP levels. The cAMP activates
the CRE-binding protein (CREB), which can then bind and
activate a CRE that controls transcription of a reporter gene
(the luciferase gene). Hence, stimulation of cells carrying the
CRE-luciferase gene with forskolin leads to increased produc-
tion of luciferase transcripts and, subsequently, to higher levels
of the luciferase protein, which can be quantified by measuring
its activity. As described above, activated Gi/0 subunits inhibit
AC. Consequently, activation of these subunits by a GPCR in
the CRE assay will result in lower luciferase levels and, thus,
lower luciferase activity. To investigate whether pR33 can ac-
tivate Gi/0 subunits, we transfected COS-7 cells with the
CRE-luciferase reporter construct and with either pcDNA3,
pcDNA3/R33, or pcDNA3/R33-EGFP. Figure 3A shows a
plasmid concentration-dependent inhibition of luciferase ac-
tivity in both pcDNA3/R33- and pcDNA3/R33-EGFP-trans-
fected cells, which indicates that pR33 can indeed constitu-
tively activate Gi/0 subunits. As expected, this activation can
be inhibited by PTX, as shown in Fig. 3B. In order to study the
specificity of this activity, we also tested constructs expressing
either CCR3, CCR10, or US28 in the CRE assay. However, in
contrast to pcDNA3/R33, these constructs did not induce an
activity significantly different from that induced by pcDNA3
alone (Fig. 3C).
pR33-mediated activation of NF-B- and SRE-driven tran-
scription. To assess the effect of constitutive pR33 signaling on
the NF-B promoter element and SRE, two additional re-
porter assays were used. In these assays, plasmid constructs are
used in which the luciferase gene is placed under the control of
either multiple SREs or the NF-B promoter element. If re-
ceptor signaling induces upregulation of the intracellular con-
centration of activated NF-B or serum response factor (SRF),
an increase in activity will be measured in the NF-B and SRE
assay, respectively. Figure 4A shows that pcDNA3/R33-trans-
fected cells have a significantly higher activity in the NF-B
assay than pcDNA3-transfected cells. As in the CRE assay, the
pR33-induced activity was completely blocked in the presence
of PTX (Fig. 4A). A similar observation was made for the
activity of pR33-EGFP in the NF-B assay (data not shown).
We conclude that pR33 induces an upregulation of activated
NF-B that is mediated via a Gi/0 protein-dependent path-
way(s). Of the other GPCRs that we tested in the NF-B assay,
only pUS28 was found to be active (Fig. 4A). As described
previously, the activation of NF-B by pUS28 is dependent not
on Gi/0 protein-dependent pathways (since it is unaffected by
the addition of PTX) but rather on Gq/11 protein-dependent
pathways (11).
Figure 4B shows that pcDNA3/R33-transfected cells also
have a significantly higher activity in the SRE assay than
pcDNA3-transfected cells. Again, this activity as well as the
activity of pcDNA3/R33-EGFP-transfected cells (data not
shown) was blocked in the presence of PTX, indicating that
pR33 induces an upregulation of activated SRF that is medi-
ated via a Gi/0 protein-dependent pathway(s). A moderate but
significant activity in the SRE assay was also measured in cells
transfected with constructs expressing pUS28 (Fig. 4B). How-
ever, in contrast to the activity of pR33, the activity of pUS28
was not significantly affected by addition of PTX.
pR33 is unable to bind RANTES. We previously reported
that pR33 shows similarity with CC-chemokine-binding
GPCRs (5, 54). In addition, the pR33 homolog from HHV-6B,
pU12, was shown to bind CC-chemokine RANTES (24). To
test whether RANTES could also bind to and/or modulate the
constitutive activity of pR33, we transfected COS-7 cells with
pcDNA3/R33 and, as a positive control, pcDNA3/pUS28 and
monitored the binding of either 125I-labeled human or rat
RANTES by the transfected cells. Although pUS28 was found
to bind human and rat RANTES with a moderate affinity (Ki 
0.9 and 15.8 nM, respectively) (Fig. 5B), binding of these che-
mokines by pR33 was not detected (Fig. 5A). Furthermore, the
addition of human or rat RANTES in the culture medium of
pcDNA3/R33-transfected COS-7 cells did not modulate the
activity of pR33 in the InsP production, NF-B, and SRE
FIG. 2. (A) Effects of G transducin subunits, GRKs, and PTX on pR33-mediated InsP accumulation. COS-7 cells were transiently transfected
with either pcDNA3 or pcDNA3/R33 in the presence of either pcDNA3/Gt (Gt), pcDNA3/GRK2 (GRK2), or pcDNA/GRK2K
220R
(GRK2K220R) (each construct at 2.0 
g of DNA/106 cells). The InsP accumulation was subsequently assessed either in the presence () or absence
() of PTX in the culture medium. (B) Effects of Gq, G16, and G11 on pR33-mediated InsP accumulation. COS-7 cells were transiently
transfected with either pcDNA3 or pcDNA3/R33 in the presence of either pcDNA3/Gq, pC1H1/G16, or pCMV5/G11, and the InsP accumu-
lation was assessed after 48 h. Representative experiments performed in triplicate are shown. Each experiment was repeated at least three times.
The asterisks indicate statistically significant differences (P  0.05) between specific results and the result from pcDNA3/R33-transfected cells.
Statistically significant differences (P  0.05) were not found between results from the pcDNA3-transfected cells. Error bars, standard error of the
mean.
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assays (Fig. 5C). The addition of rat RANTES in the CRE
assay resulted in a further inhibition of CRE-mediated tran-
scription in pcDNA3/R33-transfected cells (Fig. 5C). However,
a similar inhibitory effect of rat RANTES was seen in
pcDNA3-transfected cells (Fig. 5D), indicating that this was
not a specific pR33-mediated effect. Taken together, these
findings suggest that, unlike HHV-6B pU12, RCMV pR33
does not bind and is not responsive to RANTES. In addition,
several human chemokines of the CC (eotaxine, Teck, MCP-
1), CX3C (fractalkine), and CXC class (IP-10, IP-9, GRO-,
and interleukin-8 [IL-8]) were not able to change the activity of
pR33 significantly in any of the signaling assays used in this
study (data not shown).
pR33- and pR33-EGFP-induced stimulation of SRE-me-
diated transcription in Rat2 cells. In previous experiments,
GPCR activity was measured in COS-7 cells, which are well
characterized and highly suitable for signal transduction
studies. However, since these cells are not likely to repre-
sent appropriate hosts for efficient replication of the spe-
cies-specific RCMV, we set out to test the activity of pR33,
pR33-EGFP, and pEGFP-R33 in rat cells (Rat2). These
cells have previously been demonstrated to support full rep-
lication of RCMV (e.g., see reference 51). We first investi-
gated the expression of pR33-EGFP in Rat2 cells by confo-
cal microscopy and found the expression pattern of this
protein to be similar to that in COS-7 cells (data not shown).
This suggests that pR33-EGFP may be properly expressed
as a functional GPCR in Rat2 cells.
To test whether pR33-EGFP and pR33 are capable of
signaling in Rat2 cells, we transfected these cells with either
pcDNA3/R33 or pcDNA3/R33-EGFP and tested their ac-
tivity in the SRE assay. Indeed, both pR33 and pR33-EGFP
were found to signal in an agonist-independent, constitutive
fashion in Rat2 cells (Fig. 6), leading to a PTX-sensitive
activation of SRE-driven transcription. Thus, pR33 and
pR33-EGFP induce an upregulation of SRF that is medi-
ated via a Gi/0 protein-dependent pathway(s) in both COS-7
and Rat2 cells. As of yet, we have not been able to detect
pR33 activity in Rat2 cells in any of the other reported
assays.
FIG. 3. pR33-mediated inhibition of forskolin-induced, CRE-driven luciferase expression. (A) COS-7 cells (106) were transiently transfected
with reporter plasmid pTLNC-21CRE (5.0 
g of DNA/106 cells) and with various amounts of either pcDNA3, pcDNA3/R33, or pcDNA3/R33-
EGFP (in total, 2.0 
g of DNA/106 cells). When amounts of pcDNA3/R33 or pcDNA3/R33-EGFP lower than 2.0 
g were used, pcDNA3 was
added to include a total of 2 
g of pcDNA3-derived plasmid per transfection. At 18 h after transfection, the cells were stimulated with forskolin.
Six hours later, the CRE-driven luciferase expression and activity was quantified, and expressed as relative light units (RLU). (B) Influence of PTX
on the pR33-mediated inhibition of CRE-driven expression. PTX (100 ng/ml) was added to the culture medium at 2 h after transfection. (C)
Influence of various receptors on forskolin-stimulated, CRE-driven expression. The luciferase activity was determined similarly as described above,
after transient transfection of COS-7 cells with either pcDNA3, pcDNA3/R33 (R33), pcDNA3/CCR3 (CCR3), pcDNA3/CCR10 (CCR10), or
pcDNA3/US28 (US28) at 0.5 
g of DNA/106 cells. Data are presented as percentages of the result for the control (pcDNA3-transfected cells in
the absence of PTX). Representative experiments performed in triplicate are shown, and each experiment was repeated at least three times. An
asterisk indicates data that are statistically significantly different (P  0.05) from that for the control. Error bars, standard error of the mean.
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DISCUSSION
The biological significance of the RCMV R33-like genes in
the pathogenesis of CMV infections has previously been dem-
onstrated in studies with recombinant viruses (5, 17). In con-
trast to their WT counterparts, RCMV and MCMV mutant
viruses lacking a functional R33 or M33 gene, respectively,
were unable to replicate in the salivary glands and displayed
lower mortality rates in infected animals (5, 17). Although
these findings illustrated the importance of the R33-like genes,
not much was known about the biochemical or pharmacolog-
ical properties of the proteins encoded by these genes. Here,
we report that R33 encodes a membrane-associated protein
that functions as a GPCR. Furthermore, we demonstrate for
the first time that a member of the R33-like gene family en-
codes a constitutively active receptor that activates multiple
signaling pathways in both COS-7 and Rat2 cells.
Currently, the concept of constitutive signaling by GPCRs is
well accepted. It has been demonstrated for multiple endog-
enously expressed GPCRs, such as the H3 receptor in the rat
brain (36). Although the biological relevance is still poorly
understood, it is clear that constitutive activity can be of major
pathophysiological significance. Various diseases, including
proliferative disorders, have been described that are caused by
GPCRs that are constitutively active due to naturally occurring
mutations in these receptors (42, 43, 46, 48).
Previously, two other virus-encoded GPCRs were demon-
strated to be constitutively active. The Kaposi’s sarcoma-asso-
ciated herpesvirus (KSHV) ORF74-encoded GPCR (KSHV-
GPCR) and HCMV pUS28 both signal in an agonist-
independent fashion, resulting in constitutive activation of
various signaling pathways (2, 3, 11, 35, 45, 47). KSHV is
thought to be the causative agent of AIDS- and non-AIDS-
related Kaposi’s sarcoma as well as Castleman’s disease (12),
and the KSHV-GPCR has been proposed as a key mediator of
both the proliferative and angiogenic properties of KSHV (2,
3, 12, 28, 35, 45, 47, 57). As described in the introduction,
several interesting pUS28 activities have been suggested to be
of importance in the pathogenesis of HCMV infections. How-
ever, it is still unclear which role constitutive signaling by
pUS28 plays in these activities. Similarly, the physiological
importance of constitutive pR33 signaling remains speculative.
Both RCMV pR33 and HCMV pUS28 were found to con-
stitutively induce activation of PLC. Upon ligand binding, che-
mokine receptors also activate PLC, and this is predominantly
achieved by release of  subunits from activated, PTX-sensi-
tive Gi proteins, which stimulate the PLC isoform PLC-2 (30,
50). In addition, some chemokine receptors can activate PLC
by direct interaction with the  subunits of Gq class proteins
like Gq, G11, G14, G15, or G16 (1, 30, 50). Similarly, the
constitutive pR33-induced PLC activation involves Gq as well
as Gi/0 classes of G proteins, whereas constitutive pUS28-
mediated PLC activation is solely dependent on Gq class pro-
teins (11). Additionally, pR33 shows a remarkable level of
selectivity for G11 over Gq while pUS28 interacts both with
Gq and G11 to enhance PLC activity in COS-7 cells. A wide
variety of GPCRs, including chemokine receptors, can couple
to PLC via activation of G16, a hematopoesis-specific member
of the Gq class (34). Even receptors that selectively couple to
Gi/0 proteins, like the muscarinic acetylcholine M2 receptor,
induce InsP production in the presence of PTX when G16 is
present (34). Surprisingly, pR33-mediated constitutive PLC
activation is not enhanced by expression of G16. Since GPCR-
induced PLC activation via G16 has been demonstrated as an
agonist-mediated response, it is possible that pR33 might in-
teract with G16 only upon ligand binding and not in a ligand-
independent fashion. On the other hand, pR33 might not be
capable of G16 activation at all, as has been shown previously
for certain CC-chemokine receptors (30). Nevertheless, we
were not able to investigate these notions because at present
no ligands for pR33 have been identified.
As indicated above, pR33 constitutively couples to Gi pro-
teins, and this interaction stimulates the pR33-induced PLC
activity. Like PLC stimulation by Gi-coupled chemokine recep-
tors, this effect might be mediated by the release of Gi 
FIG. 4. pR33-mediated NF-B and SRE activation. COS-7 cells (106) were transiently transfected with either reporter plasmid pNF-B-Luc
(A) or pTLNC-3SRE (B) (5.0 
g DNA/106 cells) and with either pcDNA3, pcDNA3/R33 (R33), pcDNA3/CCR3 (CCR3), pcDNA3/CCR10
(CCR10), or pcDNA3/US28 (US28) at 0.5 
g of DNA/106 cells. At 48 h after transfection, luciferase activity was measured. The experiments were
carried out either in the presence () or absence () of PTX in the culture medium. Representative experiments performed in triplicate are
shown, and each experiment was repeated at least three times. Single asterisks indicate differences statistically significant (P 0.05) from data from
pcDNA3-transfected cells (in the absence of PTX). Double asterisks () indicate statistically significant differences (P  0.05) between data from
PTX-treated and -untreated cells that were transfected with the same expression construct. Error bars, standard error of the mean.
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subunits, because the pR33-induced PLC activity in the pres-
ence of PTX was similar to that seen in the presence of 
scavengers. Since COS-7 cells lack the PLC isoform that is
most sensitive to stimulation by Gi-derived  subunits (PLC-
2), it is likely that the pR33-induced -mediated signal ac-
tivates other PLC isoforms expressed in COS-7 cells, i.e.,
PLC-1 and PLC-3 (16, 27, 56).
In addition to PLC activation, both pR33 and pUS28 also
induce NF-B-mediated transcription in a constitutive fashion.
In the case of pUS28, this constitutive effect is due to the
activation of Gq proteins via the release of Gq  subunits (11).
Interestingly, pR33-mediated NF-B transcription is com-
pletely inhibited by PTX, indicating that this activity of pR33 is
mainly due to the activation of Gi/0 proteins. Similarly, pR33
induces SRE-mediated transcription and inhibits CRE-medi-
ated transcription in a PTX-sensitive, constitutive fashion.
These two signaling parameters, however, are not affected by
pUS28. Together with the PLC data, these findings illustrate
that although pR33 and pUS28 are both virus-encoded recep-
tors which signal constitutively, they are completely different
with regard to their respective signaling profiles.
It is likely that the PTX-sensitive, pR33-induced signaling to
CRE, SRE, and NF-B, may be mediated by the Gi2 protein,
since COS-7 cells do not endogenously express any other PTX-
sensitive G proteins apart from Gi2 (27). Previously, signaling
by Gi2 has been demonstrated to be linked to downregulation
of cytokine expression (32). Additionally, PTX-sensitive NF-
B-mediated transcription has been shown to influence the
expression of cytokines, chemokines, growth factors, and cell
adhesion molecules as well as some acute-phase proteins (15).
The induction of NF-B-mediated transcription has also been
linked to inflammatory events associated with various disease
states, such as autoimmune diseases and atherosclerosis (15).
Whether or not (the constitutive activity of) pR33 plays a role
in any of these processes during RCMV infection in vivo will
have to be addressed in future studies.
A factor that may influence the effect of (constitutive) pR33
signaling in vivo is the presence of endogenous ligands. Inter-
action of pR33 with endogenous ligands may modulate consti-
tutive activity as well as (de)activate additional signaling path-
ways. Previously, modulation of constitutive activity by agonists
and inverse agonists has been demonstrated for KSHV-GPCR
FIG. 5. pR33 does not bind rat RANTES. (A) Binding of human and rat RANTES by pUS28 and pR33. COS-7 cells were transiently
transfected with either pcDNA3, pcDNA3/US28 (US28), or pcDNA3/R33 (R33). Binding was performed 48 h after transfection on whole cells
using 6 nM 125I-labeled human or rat RANTES. Nonspecific binding was determined in the presence of 0.1 
M unlabeled competitor (human or
rat RANTES). (B) Human and rat RANTES competition curves on pUS28. COS-7 cells were transiently transfected with pcDNA3/US28 and
incubated with 0.6 nM 125I-labeled human RANTES and various amounts of unlabeled human or rat RANTES. (C) Influence of human and rat
RANTES on pR33-mediated constitutive signaling. COS-7 cells were transiently transfected with either pcDNA3 or pcDNA3/R33. Human or rat
RANTES was added to the supernatants, both in the [3H]inositol phosphate production assay (InsP) and in the reporter gene assays (CRE, NF-B,
and SRE). Data are presented as percentages of pR33 activity (100%). (D) Influence of rat RANTES on pcDNA3- and pcDNA3/R33-transfected
cells in the CRE assay. Error bars, standard error of the mean.
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and pUS28 in vitro. The constitutive activity of the KSHV-
GPCR is modulated positively by GRO- and negatively by
IP-10 and SDF-1, which are thus acting as agonist and inverse
agonists, respectively (23, 35, 44, 45). Nevertheless, not all
ligands that bind to a certain GPCR also affect the constitutive
activity of that GPCR. This was previously shown for the
KSHV-GPCR ligand IL-8 (23, 44). Similarly, pUS28 binds and
responds to various CC-chemokines, whereas none of these
CC-chemokines have been reported to modulate the constitu-
tive activity of pUS28. By contrast, fractalkine was identified as
a partial inverse agonist for pUS28, inhibiting both constitutive
PLC activation and NF-B-mediated transcription (11).
The identification of agonists and, in particular, inverse ago-
nists of constitutive viral GPCR signaling might provide valu-
able tools for elucidation of the role of this constitutive activity
in the pathogenesis of viral infection. In addition, inverse ago-
nists may be regarded as putative leads for antiviral drug de-
sign. In order to identify potential (inverse) agonists of pR33,
we tested several chemokines for modulation of pR33-medi-
ated constitutive activity. However, neither the human chemo-
kines of the CC (RANTES, eotaxine, Teck, MCP-1), CX3C
(fractalkine) or CXC class (IP-10, IP-9, GRO-, IL-8) nor the
CC-chemokine rat RANTES was able to change the activity of
pR33 significantly in any of the signaling assays used in this
study. In addition, pR33 was unable to bind RANTES, in
contrast to its homolog from HHV-6B (pU12). The latter
protein was shown to bind RANTES, MCP-1, and MIP-1 as
well as MIP-1, resulting in an intracellular calcium flux (25).
These findings illustrate that individual members of the R33
family can have significantly different ligand-binding character-
istics.
Taken together, we found pR33 to activate and inhibit var-
ious signaling pathways in the absence of exogenously added
ligands. However, it cannot be ruled out that the activity of
pR33 is the result of binding of yet-unidentified, endogenously
produced ligands. In this respect it is interesting that a novel
CC-chemokine was identified, CCL28, which is a ligand for
both CCR10 and CCR3 (39, 55). This chemokine, also known
as mucosa-associated epithelial chemokine, is expressed in hu-
man and murine epithelial cells of diverse mucosal tissues and
directs chemotaxis of CCR10-expressing lymphoid cells. Inter-
estingly, CCL28 transcripts are most abundant in the salivary
glands (39). With respect to the sequence similarity between
CCR10, CCR3, and pR33, we hypothesized that the ability of
RCMV to establish a successful infection within the salivary
glands could be dependent on the interaction of a CCL28-like
chemokine with pR33 (54). This putative interaction of pR33
with the rat homolog of CCL28 is currently under investiga-
tion.
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